Bioventus Inc.: BROWN ADVISORY INC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Brown Advisory Inc. disclosed a stake exceeding 5% in Bioventus Inc. via a Schedule 13G filing with the SEC (accession 0001345929-26-000044). The passive-investor disclosure signals a significant institutional position in the medical device maker. The exact share count and percentage were not specified in the filing summary. Investors will watch for further 13G amendments and Bioventus's next quarterly update for clarity on the holder's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Bioventus Inc., Brown Advisory Inc.